Form 13-F position report

BRAINSTORM CELL THERAPEUTICS I

Reported by MORGAN STANLEY

BCLI CUSIP 10501E300 Manager CIK 0000895421

Reported 0 shares, down 5,803 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q3 2025
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 4 Through Q3 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2024-12-31 9800
2025-03-31 5466
2025-06-30 6499
2025-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

4 quarters
Quarterly reported position history for BRAINSTORM CELL THERAPEUTICS I held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2025 Reduced 0 -5,803 (-100.0%) 0 $0 2025-11-14
Q2 2025 Added 5,803 +1,465 (33.8%) < 0.01% $6,499 2025-08-15
Q1 2025 Added 4,338 +21 (0.5%) < 0.01% $5,466 2025-05-15
Q4 2024 New 4,317 +4,317 (0.0%) < 0.01% $9,800 2025-02-14

Who else reported the position

34 managers reported BRAINSTORM CELL THERAPEUTICS I for Q3 2025.

Managers reporting BRAINSTORM CELL THERAPEUTICS I in Q3 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
ADVISOR GROUP HOLDINGS INC Unchanged 1,785 0 < 0.01% $1,351 4 qtrs
Bangor Savings Bank Unchanged 266 0 < 0.01% $188 3 qtrs
VSM Wealth Advisory LLC Unchanged 120 0 < 0.01% $85 3 qtrs
Steward Partners Investment Advisory LLC Unchanged 113 0 < 0.01% $80 4 qtrs
ST GERMAIN D J CO INC Unchanged 33 0 < 0.01% $23 5 qtrs
CoreCap Advisors LLC Reduced 0 -8 0 $0 4 qtrs
CBIZ Investment Advisory Services LLC Reduced 0 -13 0 $0 4 qtrs
JONES FINANCIAL COMPANIES LLLP Reduced 0 -216 0 $0 3 qtrs
Weaver Consulting Group Reduced 0 -15,623 0 $0 3 qtrs
Activest Wealth Management Reduced 0 -334 0 $0 4 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2025
Filed
November 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.